Pharmaceutical and Biotechnology Industry Insights: Innovative Pharmaceuticals and Medical Devices Drive Structural Market Trends; AI in Healthcare Opens Up New Growth Opportunities.
Release time:
2025-03-01
During the third week of February 2025, the pharmaceutical and biotechnology sector continued its pattern of structural divergence. Throughout the week, the pharmaceutical and biotechnology index rose by 1.88%, outperforming both the CSI 300 and the Shanghai Composite Index, and ranking ninth in terms of sector gain or loss.
During the third week of February 2025, the pharmaceutical and biotechnology sector continued its pattern of structural divergence. Throughout the week, the pharmaceutical and biotechnology index rose by 1.88%, outperforming both the CSI 300 and the Shanghai Composite Index, ranking ninth in terms of sector gains and losses. Among sub-sectors, medical R&D outsourcing led the way with a gain of 11.3%, while offline pharmacies experienced a decline of 3.06%, making them the weakest-performing sub-sector. In terms of sector valuation, the current price-to-earnings ratio (TTM) stands at 26 times, remaining in the lower range of the past decade. Market capital continues to flow toward hard-tech sectors such as innovative drugs and AI-driven healthcare, and positive signals from policy makers have further strengthened expectations for a bottom-up reversal in the industry.
Although AI in healthcare holds great promise, its development still faces challenges such as data compliance issues and lengthy clinical validation cycles. Currently, the market tends to favor midstream platform companies in the “AI + Healthcare” space—these companies, by integrating algorithms, data, and clinical resources, can rapidly achieve technology transfer. Meanwhile, emerging technological areas such as stem-cell therapy and gene editing are increasingly demonstrating synergistic effects with AI, and could become key battlegrounds for future industry competition. It’s worth noting that striking a balance between the pace of technological iteration and regulatory adaptability will be a critical factor determining the industry’s growth trajectory.
Previous
Address: 6th Floor, Building C6, Jiangsu Life Science and Technology Innovation Park, Qixia District, Nanjing City
Official account